Certain Maternal Antibodies in Relation to Doppler in Hypertension With Pregnancy

Pre-Eclampsia Clinical Trial

Official title:

Role of Maternal Anticardiolipin and Anti-B2 Glycoprotein I Antibodies in Correlation With Fetal Doppler in Prediction of Adverse Pregnancy Outcome in Patients With Preeclampsia

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03214393
• Other study ID #: 3650
• Status: Not yet recruiting
• Phase: N/A
• First received: July 10, 2017
• Last updated: July 10, 2017
• Start date: August 1, 2017
• Est. completion date: August 30, 2018

Study information

• Verified date: July 2017
• Source: Cairo University
• Contact: Doaa Sh Belal, MD
• Phone: 0020223682030
• Email: doaash[@]live.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Relation of certain maternal serum antibodies to Doppler changes will be studied in cases suffering from hypertension with pregnancy.

Description:

Assessment will be done for maternal serum anti-beta 2 glycoprotein 1 antibodies and anticardiolipin antibodies in cases of preeclampsia after 32 weeks of pregnancy. In addition, fetal Doppler changes will be assessed.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: August 30, 2018
• Est. primary completion date: July 30, 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pregnant women 32 weeks or more gestational age

• Pre-eclampsia

• Singleton pregnancy

Exclusion Criteria:

• Intrauterine fetal death

• Fetus with apparent congenital anomalies

• Pregnant females with other medical disorders

• History of essential hypertension.

• History of antepartum hemorrhage.

• History of rupture of membranes.

Related Conditions & MeSH terms

• Eclampsia
• Pre-Eclampsia

Intervention

Diagnostic Test:
• Doppler
Doppler will be done to pregnant women with Pre-Eclampsia
• serum antibodies
serum antibodies will be measured for pregnant women with Pre-Eclampsia

Locations

Country	Name	City	State
Egypt	Department of Obstetrics and Gynecology	Cairo	Greater Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	percentage of cases that develop severe pre-eclampsia	percentage of cases that develop severe pre-eclampsia will be assessed by an investigator	It will be calculated after 1 year from the start of the study